Effect of comorbidity on quality of life and treatment selection in patients with squamous cell carcinoma of the head and neck

Christine G. Gourin, William J. McAfee, Kimberly M. Neyman, Jed W. Howington, Robert H. Podolsky, David J Terris

Research output: Contribution to journalReview article

30 Citations (Scopus)

Abstract

Objectives: Comorbidity is significantly associated with diminished survival and quality of life (QOL) after treatment of head and neck squamous cell carcinoma (HNSCC). We sought to determine whether comorbidity influenced pretreatment QOL scores and treatment selection in patients with HNSCC. Methods: The medical records of all patients diagnosed with HNSCC who participated in pretreatment QOL analysis over a 15-month period were retrospectively reviewed. Patients with a history of prior treatment for head and neck cancer, unresectable, or distant metastatic disease were excluded. The University of Washington (UW) QOL questionnaire, Performance Status Scale (PSS), and Karnofsky score were used to measure pretreatment QOL. Comorbidity was graded using the Modified Medical Comorbidity Index. Results: Of 75 patients who met study criteria, 33 underwent primary surgical therapy, and 42 underwent nonoperative (radiation or chemoradiation) therapy. Treatment groups did not differ with respect to patient demographics, UW QOL scores, PSS scores, Karnofsky score, or comorbidity. Treatment groups differed significantly by disease stage and primary site. Patients with advanced stage disease (III/ IV) or oropharyngeal primary tumors were more likely to undergo nonoperative treatment, compared with patients with early stage disease (I/II) or oral cavity primary tumors (P < .005). No significant association was found between comorbidity and pretreatment QOL scores. Conclusions: Comorbidity was not significantly associated with treatment selection or pretreatment QOL scores in patients with HNSCC. Location of the primary tumor and disease stage were significantly associated with treatment selection. Further studies are required to determine the effect of comorbidity on patient and tumor responses to treatment.

Original languageEnglish (US)
Pages (from-to)1371-1375
Number of pages5
JournalLaryngoscope
Volume115
Issue number8
DOIs
StatePublished - Aug 1 2005

Fingerprint

Patient Selection
Comorbidity
Quality of Life
Therapeutics
Karnofsky Performance Status
Neoplasms
Carcinoma, squamous cell of head and neck
Head and Neck Neoplasms
Medical Records
Mouth
Demography
Radiation
Survival

Keywords

  • Comorbidity
  • Head and neck neoplasms
  • Quality of life
  • Squamous cell cancer
  • Treatment

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Effect of comorbidity on quality of life and treatment selection in patients with squamous cell carcinoma of the head and neck. / Gourin, Christine G.; McAfee, William J.; Neyman, Kimberly M.; Howington, Jed W.; Podolsky, Robert H.; Terris, David J.

In: Laryngoscope, Vol. 115, No. 8, 01.08.2005, p. 1371-1375.

Research output: Contribution to journalReview article

Gourin, Christine G. ; McAfee, William J. ; Neyman, Kimberly M. ; Howington, Jed W. ; Podolsky, Robert H. ; Terris, David J. / Effect of comorbidity on quality of life and treatment selection in patients with squamous cell carcinoma of the head and neck. In: Laryngoscope. 2005 ; Vol. 115, No. 8. pp. 1371-1375.
@article{fba2811bb6c94eb7a14f13090ab3b4b9,
title = "Effect of comorbidity on quality of life and treatment selection in patients with squamous cell carcinoma of the head and neck",
abstract = "Objectives: Comorbidity is significantly associated with diminished survival and quality of life (QOL) after treatment of head and neck squamous cell carcinoma (HNSCC). We sought to determine whether comorbidity influenced pretreatment QOL scores and treatment selection in patients with HNSCC. Methods: The medical records of all patients diagnosed with HNSCC who participated in pretreatment QOL analysis over a 15-month period were retrospectively reviewed. Patients with a history of prior treatment for head and neck cancer, unresectable, or distant metastatic disease were excluded. The University of Washington (UW) QOL questionnaire, Performance Status Scale (PSS), and Karnofsky score were used to measure pretreatment QOL. Comorbidity was graded using the Modified Medical Comorbidity Index. Results: Of 75 patients who met study criteria, 33 underwent primary surgical therapy, and 42 underwent nonoperative (radiation or chemoradiation) therapy. Treatment groups did not differ with respect to patient demographics, UW QOL scores, PSS scores, Karnofsky score, or comorbidity. Treatment groups differed significantly by disease stage and primary site. Patients with advanced stage disease (III/ IV) or oropharyngeal primary tumors were more likely to undergo nonoperative treatment, compared with patients with early stage disease (I/II) or oral cavity primary tumors (P < .005). No significant association was found between comorbidity and pretreatment QOL scores. Conclusions: Comorbidity was not significantly associated with treatment selection or pretreatment QOL scores in patients with HNSCC. Location of the primary tumor and disease stage were significantly associated with treatment selection. Further studies are required to determine the effect of comorbidity on patient and tumor responses to treatment.",
keywords = "Comorbidity, Head and neck neoplasms, Quality of life, Squamous cell cancer, Treatment",
author = "Gourin, {Christine G.} and McAfee, {William J.} and Neyman, {Kimberly M.} and Howington, {Jed W.} and Podolsky, {Robert H.} and Terris, {David J}",
year = "2005",
month = "8",
day = "1",
doi = "10.1097/01.mlg.0000167983.32017.64",
language = "English (US)",
volume = "115",
pages = "1371--1375",
journal = "Laryngoscope",
issn = "0023-852X",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Effect of comorbidity on quality of life and treatment selection in patients with squamous cell carcinoma of the head and neck

AU - Gourin, Christine G.

AU - McAfee, William J.

AU - Neyman, Kimberly M.

AU - Howington, Jed W.

AU - Podolsky, Robert H.

AU - Terris, David J

PY - 2005/8/1

Y1 - 2005/8/1

N2 - Objectives: Comorbidity is significantly associated with diminished survival and quality of life (QOL) after treatment of head and neck squamous cell carcinoma (HNSCC). We sought to determine whether comorbidity influenced pretreatment QOL scores and treatment selection in patients with HNSCC. Methods: The medical records of all patients diagnosed with HNSCC who participated in pretreatment QOL analysis over a 15-month period were retrospectively reviewed. Patients with a history of prior treatment for head and neck cancer, unresectable, or distant metastatic disease were excluded. The University of Washington (UW) QOL questionnaire, Performance Status Scale (PSS), and Karnofsky score were used to measure pretreatment QOL. Comorbidity was graded using the Modified Medical Comorbidity Index. Results: Of 75 patients who met study criteria, 33 underwent primary surgical therapy, and 42 underwent nonoperative (radiation or chemoradiation) therapy. Treatment groups did not differ with respect to patient demographics, UW QOL scores, PSS scores, Karnofsky score, or comorbidity. Treatment groups differed significantly by disease stage and primary site. Patients with advanced stage disease (III/ IV) or oropharyngeal primary tumors were more likely to undergo nonoperative treatment, compared with patients with early stage disease (I/II) or oral cavity primary tumors (P < .005). No significant association was found between comorbidity and pretreatment QOL scores. Conclusions: Comorbidity was not significantly associated with treatment selection or pretreatment QOL scores in patients with HNSCC. Location of the primary tumor and disease stage were significantly associated with treatment selection. Further studies are required to determine the effect of comorbidity on patient and tumor responses to treatment.

AB - Objectives: Comorbidity is significantly associated with diminished survival and quality of life (QOL) after treatment of head and neck squamous cell carcinoma (HNSCC). We sought to determine whether comorbidity influenced pretreatment QOL scores and treatment selection in patients with HNSCC. Methods: The medical records of all patients diagnosed with HNSCC who participated in pretreatment QOL analysis over a 15-month period were retrospectively reviewed. Patients with a history of prior treatment for head and neck cancer, unresectable, or distant metastatic disease were excluded. The University of Washington (UW) QOL questionnaire, Performance Status Scale (PSS), and Karnofsky score were used to measure pretreatment QOL. Comorbidity was graded using the Modified Medical Comorbidity Index. Results: Of 75 patients who met study criteria, 33 underwent primary surgical therapy, and 42 underwent nonoperative (radiation or chemoradiation) therapy. Treatment groups did not differ with respect to patient demographics, UW QOL scores, PSS scores, Karnofsky score, or comorbidity. Treatment groups differed significantly by disease stage and primary site. Patients with advanced stage disease (III/ IV) or oropharyngeal primary tumors were more likely to undergo nonoperative treatment, compared with patients with early stage disease (I/II) or oral cavity primary tumors (P < .005). No significant association was found between comorbidity and pretreatment QOL scores. Conclusions: Comorbidity was not significantly associated with treatment selection or pretreatment QOL scores in patients with HNSCC. Location of the primary tumor and disease stage were significantly associated with treatment selection. Further studies are required to determine the effect of comorbidity on patient and tumor responses to treatment.

KW - Comorbidity

KW - Head and neck neoplasms

KW - Quality of life

KW - Squamous cell cancer

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=23344445463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23344445463&partnerID=8YFLogxK

U2 - 10.1097/01.mlg.0000167983.32017.64

DO - 10.1097/01.mlg.0000167983.32017.64

M3 - Review article

C2 - 16094107

AN - SCOPUS:23344445463

VL - 115

SP - 1371

EP - 1375

JO - Laryngoscope

JF - Laryngoscope

SN - 0023-852X

IS - 8

ER -